MK-8808 (rituximab biosimilar) / Merck (MSD) - LARVOL DELTA

Dr. Reddy’s targets Roche’s Rituxan in Europe: Corporate India (Bloomberg Business Week) - "Dr. Reddy’s Laboratories...aims to be among the first three to four companies offering copies of biotechnology drugs, including a version of Roche Holding AG (ROG)’s Rituxan, in Europe....The companies [Reddy’s Laboratories & Merck Serono] aim to together develop, manufacture and commercialize a portfolio of four biosimilar drugs...copies of Roche’s blockbuster rituximab and Amgen Inc.’s blood-related therapies filgrastim, pegfilgrastim and darbepoetin alfa."

Anticipated launch Europe • Biosimilar • Hematological Malignancies

A study of the pharmacokinetics and safety of MK-8808 (MK-8808-002 AM4 EXT 1) (clinicaltrials.gov) - P1, N=180; Sponsor: Merck; Active, not recruiting; Completion date: Feb 2016 -> May 2014.

Trial completion date • Biosimilar

Study of MK-8808 for participants with follicular lymphoma (MK-8808-001) (clinicaltrials.gov) - P1, N=22; Sponsor: Merck;  Active, not recruiting; Primary completion date: Dec 2014 -> Sep 2015.

Trial primary completion date • Biosimilar